Cargando…

Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents

We describe two adults with A/H3N2 influenza with (patient 1), and without (patient 2) polymerase acidic (PA) subunit I38 T substitution during the same season. Patient 1 had a reduced clinical response to baloxavir, a cap-dependent endonuclease inhibitor (CEI), but was cured by peramivir, a neurami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seki, Masafumi, Sakai-Tagawa, Yuko, Yasuhara, Atsuhiro, Watanabe, Yuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804930/ https://www.ncbi.nlm.nih.gov/pubmed/31692637 http://dx.doi.org/10.1016/j.idcr.2019.e00650

Ejemplares similares

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020)

Peramivir for influenza
Publicado: (2019)

Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
por: Kamioka, Yasuhiro, et al.
Publicado: (2020)

Peramivir and laninamivir susceptibility of circulating influenza A and B viruses
por: Leang, Sook-Kwan, et al.
Publicado: (2014)

Safety and efficacy of peramivir for influenza treatment
por: Hata, Atsuko, et al.
Publicado: (2014)

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
por: Mishin, Vasiliy P., et al.
Publicado: (2019)

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018)

Modeling mitigation of influenza epidemics by baloxavir
por: Du, Zhanwei, et al.
Publicado: (2020)

A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
por: Yasuhara, Atsuhiro, et al.
Publicado: (2022)

Peramivir injection in the treatment of acute influenza: a review of the literature
por: Wester, Ashley, et al.
Publicado: (2016)

Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil
por: Nakauchi, Mina, et al.
Publicado: (2020)

Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020)

Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021)

Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019
por: Takashita, Emi, et al.
Publicado: (2019)

Single Dose IV Peramivir is Safe and Effective in the Treatment of Pediatric Influenza
por: Vanchiere, John, et al.
Publicado: (2017)

A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid
por: Takizawa, Naoki, et al.
Publicado: (2022)

Clinical Effectiveness of Peramivir in Comparison with Other Neuraminidase Inhibitors in Pediatric Influenza Patients
por: Hikita, Toshiyuki, et al.
Publicado: (2012)

Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections
por: Alame, Malak M., et al.
Publicado: (2016)

A Case of Influenza Associated Fulminant Myocarditis Successfully Treated with Intravenous Peramivir
por: Baik, Seung Hee, et al.
Publicado: (2015)

Clinical Effectiveness and Safety of Peramivir for Influenza Infection: Safe and Effective Antiviral Treatment
por: Lee, Jin Seo
Publicado: (2018)

Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection
por: Pascua, Philippe Noriel Q., et al.
Publicado: (2017)

Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients
por: Lee, Jin Seo, et al.
Publicado: (2020)

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020)

Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model
por: Lee, Leo Y, et al.
Publicado: (2021)

Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects
por: Zhang, Chen-xi, et al.
Publicado: (2022)

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons
por: Gubareva, Larisa V, et al.
Publicado: (2019)

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
por: Takashita, Emi, et al.
Publicado: (2019)

Use of Intravenous Peramivir in a Critically Ill Toddler With Influenza A Infection and Cardiac Involvement
por: Chaudhary, Manu, et al.
Publicado: (2015)

Detection of Peramivir and Laninamivir, New Anti-Influenza Drugs, in Sewage Effluent and River Waters in Japan
por: Azuma, Takashi, et al.
Publicado: (2015)

Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis
por: Lee, Jonghoo, et al.
Publicado: (2017)

A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment
por: Chen, Jui-Yi, et al.
Publicado: (2020)

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)

The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2020)

The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice
por: Yoshii, Naoko, et al.
Publicado: (2020)

97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant
por: Checkmahomed, Liva, et al.
Publicado: (2019)

2645. Clinical Outcomes of Oseltamivir vs. Baloxavir in Patients Hospitalized with Influenza A
por: Shah, Sunish, et al.
Publicado: (2019)

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals
por: Liu, Yanmei, et al.
Publicado: (2022)

Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018–2019 Influenza Season
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2019)

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020
por: Govorkova, Elena A., et al.
Publicado: (2022)

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019
por: Takashita, Emi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iv2hg62gpnkhle2m6b9rferrum